Outlook Therapeutics Inc OTLK

NAS: OTLK | ISIN: US69012T2069   30/04/2025
1,570 USD (+0,64%)
(+0,64%)   30/04/2025

4 december 2024 · Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD · Persbericht

8 juli 2024 · Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD · Persbericht

28 december 2023 · OTLK Investors Have Opportunity to Lead Outlook Therapeutics, Inc. Securities Fraud Lawsuit · Persbericht

28 december 2023 · OUTLOOK INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options · Persbericht

21 december 2023 · OUTLOOK INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options · Persbericht

14 december 2023 · OTLK Investors Have Opportunity to Lead Outlook Therapeutics, Inc. Securities Fraud Lawsuit · Persbericht

5 december 2023 · OUTLOOK SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options · Persbericht

13 november 2023 · Outlook Investor Deadline Approaching · Persbericht

13 november 2023 · SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Outlook Investors of a Lead Plaintiff Deadline of January 2, 2024 · Persbericht

11 november 2023 · SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Outlook Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - OTLK · Persbericht

11 november 2023 · ROSEN, AN INVESTOR RIGHTS LAW FIRM, Encourages Outlook Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - OTLK · Persbericht

9 november 2023 · Outlook Therapeutics, Inc. Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against Outlook Therapeutics, Inc. · Persbericht

9 november 2023 · SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc.(OTLK) Investors of a Class Action Lawsuit and Upcoming Deadline · Persbericht

4 november 2023 · Pomerantz Law Firm Announces the Filing of a Class Action Against Outlook Therapeutics, Inc. and Certain Officers - OTLK · Persbericht

4 november 2023 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Outlook Therapeutics, Inc. - OTLK · Persbericht

26 oktober 2023 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Outlook Therapeutics, Inc. - OTLK · Persbericht

20 oktober 2023 · Thinking about buying stock in Ardelyx, Rivian Automotive, Femasys, Lucid Group, or Outlook Therapeutics? · Persbericht

18 oktober 2023 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Outlook Therapeutics, Inc. - OTLK · Persbericht

9 oktober 2023 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Outlook Therapeutics, Inc. - OTLK · Persbericht

29 september 2023 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Outlook Therapeutics, Inc. - OTLK · Persbericht

Mijn selecties